Abstract:HIV-1 based lentiviral viruses are considered powerful and versatile gene therapy vectors to deliver therapeutic genes to patients with hereditary or acquired diseases. These vectors can efficiently transduce a variety of cell types when dividing or non-dividing to provide permanent delivery and long-term gene expression. Demand for scalable manufacturing protocols able to generate enough high titre vector for widespread use of this technology is increasing and considerable efforts to improve vector production cost-effectively, is ongoing. Current methods for LV production mainly use transient transfection of producer cell lines. Cells can be grown at scale, either in 2D relying on culturing producer cells in multi-tray flask cell culture factories or in roller bottles or can be adapted to grow in 3D suspensions in large batch fermenters. This suits rapid production and testing of new vector constructs pre-clinically for their efficacy, particle titre and safety. In this study, we sought to improve lentiviral titre over time by testing two alternative commercially available transfection reagents Fugene® 6 and Genejuice® with the commonly used polycation, polyethyleneimine. Our aim was to identify less cytotoxic transfection reagents that could be used to generate LV particles at high titre past the often used 72 hour period when vector is usually collected before producer cell death is caused due to post transfection cytotoxicity. We show that LV could be produced in extended culture using Genejuice® and even by transfected cells in glass flasks in suspension. Because this delivery agent is less toxic to 293T producer cells, following optimisation of transfection we found that LV can be harvested for more than 10 days at high titre. Using our protocol, titres of 10 9 TU/ml and 10 8 TU/ml were routinely reached via traditional monolayer conditions or suspension cultures, respectively. We propose, this simple change in vector production enables large volumes of high titre vector to be produced, cost effectively for non-clinical in vivo and in vitro applications or for more stringent downstream clinical grade vector purification.

Optimization of packaging the HIV-1 pseudotyped virus

Endodomain truncation of the HIV-1 envelope protein improves the packaging efficiency of pseudoviruses

An improved HAdV-41 E1B55K-expressing 293 cell line for packaging fastidious adenovirus.

Optimized protocol for high‐titer lentivirus production and transduction of primary fibroblasts

On Judgements and Propositions

Optimization and Proficiency Testing of a Pseudovirus-Based Assay for Detection of HIV-1 Neutralizing Antibody in China.

Characterization of a new pseudotyped HIV with a single-round infectivity carrying enhanced green fluorescent protein gene

Treg Cell Evaluation in Patients with Acquired Immune Deficiency Syndrome with Poor Immune Reconstitution and Human Immunodeficiency Virus-Infected Treg Cell Prevention by Polymeric Nanoparticle Drug Delivery System.

Generation of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors

Production of pseudotyped human immunodeficiency virus-1 and analysis on its ability to infect the primary effusion lymphoma cell line

Efficient gene transfer mediated by HIV-1-based defective lentivector and inhibition of HIV-1 replication

An optimized method for high-titer lentivirus preparations without ultracentrifugation

Optimised protocols to generate high titre lentiviral vectors using a novel transfection agent enabling extended HEK293T culture following transient transfection and suspension culture

Expression, Purification and Characterization of Hiv-1 Capsid Precursor Protein p41

Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins

Optimization of SARS-CoV-2 Pseudovirion Production in Lentivirus Backbone With a Novel Liposomal System

Optimization of Production Procedure of Replicating Recombinant Live Vaccinia Virus Vector-based Vaccine

Establishment of Chinese Prevalent Stains of HIV-1 Pseudovirus and Its Preliminary Application

Continuous high-titer HIV-1 vector production

Production of Lentiviral Vectors in Suspension Cells Using Low Proportion of Supercoiled Circular Plasmid DNA

Design and in vitro delivery of HIV-1 multi-epitope DNA and peptide constructs using novel cell-penetrating peptides